大阪大学大学院 健康発達医学
HOME研究内容紹介 > 生活習慣病・難治性疾患を標的とした治療ワクチンの開発
研究内容紹介

生活習慣病・難治性疾患を標的とした治療ワクチンの開発

超高齢化社会の今、社会構造の変化や抗体医薬などの高価な医療の出現により、今後の我が国の医療の在り方において疾患の治療法にはコストや効率などを考慮したより多くの選択肢が求められています。私たちは生活習慣病に対するワクチンが疾患治療の一つの選択肢となりうるのではないかと考え、ペプチドあるいはDNAワクチンに注目し研究開発を行っています。生活習慣病治療の新規治療法の実用化に向けた産学連携の研究体制を確立するために産学連携体制で進めています。

Vaccines are primarily used worldwide as a preventive medicine for infectious diseases and have recently been applied to cancer. We and others have developed therapeutic vaccines designed for cardiovascular diseases that are notably different from previous vaccines. In the case of cancer vaccines, a specific protein in cancer cells is a target antigen, and the activation of cytotoxic T cells (CTL) is required to kill and remove the antigen-presenting cancer cells. Our therapeutic vaccines work against hypertension by targeting angiotensin II (Ang II) as the antigen, which is an endogenous hormone. Therapeutic vaccines must avoid CTL activation and induce the blocking antibodies for Ang II. The goal of our therapeutic vaccine for cardiovascular diseases is to induce the specific antibody response toward the target protein without inducing T-cell or antibody-mediated inflammation through the careful selection of the target antigen, carrier protein and adjuvants. The goal of our therapeutic vaccine is similar to that of antibody therapy. Recently, multiple antibody-based drugs have been developed for cancer, immune-related diseases and dyslipidemia, which are efficient but expensive. If the effect of a therapeutic vaccine is nearly equivalent to antibody therapy as an alternative approach, the lower medical cost and improvement of drug adherence can be advantages of therapeutic vaccines. We will develop the novel concept of therapeutic vaccines and show the future directions as novel antibody therapies.

ページの先頭へ